Alanine scanning mutagenesis of the MEDI4839 (Suvratoxumab) epitope reduces alpha toxin lytic activity <i>in vitro</i> and <i>S. aureus</i> fitness in infection models
bioRxiv (Cold Spring Harbor Laboratory)